MSD Calls For Preventing 'Blatant' India Patent Violations Like Glenmark's
This article was originally published in PharmAsia News
Executive Summary
Merck Sharp and Dohme has expressed concern about what it terms Glenmark's "blatant" violation of two patents for Januvia (sitagliptin) diabetes drug also sold as Janumet.